It is noteworthy that MYCN-amplified neuroblastoma cell lines are inherently more sensitive to the growth-inhibitory effects of MDM2-p53 antagonists compared with non-MYCN-amplified neuroblastoma cell lines.172. This evidence concerns the gene MDM2 and neuroblastoma.